Advertisement

Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma

  • Author Footnotes
    # These authors contributed equally to this work.
    Hao Xu
    Footnotes
    # These authors contributed equally to this work.
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Author Footnotes
    # These authors contributed equally to this work.
    Qiuxia Lv
    Footnotes
    # These authors contributed equally to this work.
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Liang Huang
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Wenyue Cao
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Jue Wang
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Fankai Meng
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Chunrui Li
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Miao Zheng
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Liting Chen
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Ketao Mu
    Affiliations
    Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    Search for articles by this author
  • Jiali Cheng
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Li Zhu
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Jianfeng Zhou
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Yicheng Zhang
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Na Wang
    Correspondence
    Correspondence: Na Wang, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jie Fang Avenue, Wuhan 430030, China.
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Yang Cao
    Correspondence
    Correspondence: Yang Cao, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jie Fang Avenue, Wuhan 430030, China.
    Affiliations
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
    Search for articles by this author
  • Author Footnotes
    # These authors contributed equally to this work.
Published:October 22, 2022DOI:https://doi.org/10.1016/j.jcyt.2022.10.001
      Indolent lymphomas, including follicular lymphoma (FL), marginal zone lymphoma, lymphoplasmacytic lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma, are characterized by a prolonged waxing and waning of the disease course and relatively long survival in most patients compared with their aggressive lymphoma counterparts. However, indolent lymphomas have the potential to transform into more aggressive lymphomas. Patients with FL have a transformation rate of 2–3% per year [
      • Pasqualucci L
      • Khiabanian H
      • Fangazio M
      • et al.
      Genetics of Follicular Lymphoma Transformation.
      ,
      • Link BK
      • Maurer MJ
      • Nowakowski GS
      • et al.
      Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report from the University of Iowa/Mayoclinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
      ,
      • Wagner-Johnston ND
      • Link BK
      • Byrtek M
      • et al.
      Outcomes of Transformed Follicular Lymphoma in the Modern Era: A Report from the National Lymphocare Study (Nlcs).
      ], and the most common histological transformation subtype is diffuse large B-cell lymphoma (DLBCL), and transformation to other histological subtypes, such as Burkitt lymphoma, lymphoblastic lymphoma, acute lymphoblastic leukemia and even Hodgkin lymphoma, is also seen. This type of transformation is often associated with rapid disease progression, resistance to initial therapy and poor prognosis [
      • Link BK
      • Maurer MJ
      • Nowakowski GS
      • et al.
      Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report from the University of Iowa/Mayoclinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
      ,
      • Sarkozy C
      • Trneny M
      • Xerri L
      • et al.
      Risk Factors and Outcomes for Patients with Follicular Lymphoma Who Had Histologic Transformation after Response to First-Line Immunochemotherapy in the Prima Trial.
      ,
      • Montoto S
      • Davies AJ
      • Matthews J
      • et al.
      Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma.
      ]. With the use of rituximab, overall survival (OS) has improved significantly in most transformed lymphoma patients, but a proportion of patients fail to achieve remission or relapse after standard therapy [
      • Link BK
      • Maurer MJ
      • Nowakowski GS
      • et al.
      Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report from the University of Iowa/Mayoclinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
      ].

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pasqualucci L
        • Khiabanian H
        • Fangazio M
        • et al.
        Genetics of Follicular Lymphoma Transformation.
        Cell Rep. 2014; 6: 130-140
        • Link BK
        • Maurer MJ
        • Nowakowski GS
        • et al.
        Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report from the University of Iowa/Mayoclinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
        J Clin Oncol. 2013; 31: 3272-3278
        • Wagner-Johnston ND
        • Link BK
        • Byrtek M
        • et al.
        Outcomes of Transformed Follicular Lymphoma in the Modern Era: A Report from the National Lymphocare Study (Nlcs).
        Blood. 2015; 126: 851-857
        • Sarkozy C
        • Trneny M
        • Xerri L
        • et al.
        Risk Factors and Outcomes for Patients with Follicular Lymphoma Who Had Histologic Transformation after Response to First-Line Immunochemotherapy in the Prima Trial.
        J Clin Oncol. 2016; 34: 2575-2582
        • Montoto S
        • Davies AJ
        • Matthews J
        • et al.
        Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma.
        J Clin Oncol. 2007; 25: 2426-2433
        • Schuster SJ
        • Bishop MR
        • Tam CS
        • et al.
        Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
        N Engl J Med. 2019; 380: 45-56
        • Fry TJ
        • Shah NN
        • Orentas RJ
        • et al.
        Cd22-Targeted Car T Cells Induce Remission in B-All That Is Naive or Resistant to Cd19-Targeted Car Immunotherapy.
        Nat Med. 2018; 24: 20-28
        • Spiegel JY
        • Patel S
        • Muffly L
        • et al.
        Car T Cells with Dual Targeting of Cd19 and Cd22 in Adult Patients with Recurrent or Refractory B Cell Malignancies: A Phase 1 Trial.
        Nat Med. 2021; 27: 1419-1431
        • Wang N
        • Hu X
        • Cao W
        • et al.
        Efficacy and Safety of Car19/22 T-Cell Cocktail Therapy in Patients with Refractory/Relapsed B-Cell Malignancies.
        Blood. 2020; 135: 17-27
        • Cao Y
        • Xiao Y
        • Wang N
        • et al.
        CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
        Transplant Cell Ther. 2021; 27: 910.e1-910.e11
        • Wei J
        • Xiao M
        • Mao Z
        • et al.
        Outcome of Aggressive B-Cell Lymphoma with Tp53 Alterations Administered with Car T-Cell Cocktail Alone or in Combination with Asct.
        Signal Transduct Target Ther. 2022; 7: 101
        • Wei J
        • Mao Z
        • Wang N
        • et al.
        Long-Term Outcomes of Relapsed/Refractory Double-Hit Lymphoma (R/R Dhl) Treated with Cd19/22 Car T-Cell Cocktail Therapy.
        Clin Transl Med. 2020; 10: e176
        • Xu H
        • Cao W
        • Huang L
        • et al.
        Effects of Cryopreservation on Chimeric Antigen Receptor T Cell Functions.
        Cryobiology. 2018; 83: 40-47
        • Ding S
        • Mao X
        • Cao Y
        • Wang N
        • Xu H
        • Zhou J
        Targeting Cd79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas.
        Target Oncol. 2020; 15: 365-375
        • Xu H
        • Wang N
        • Cao W
        • Huang L
        • Zhou J
        • Sheng L
        Influence of Various Medium Environment to In Vitro Human T Cell Culture.
        In Vitro Cell Dev Biol Anim. 2018; 54: 559-566
        • Cheson BD
        • Pfistner B
        • Juweid ME
        • et al.
        Revised Response Criteria for Malignant Lymphoma.
        J Clin Oncol. 2007; 25: 579-586
        • Zeng C
        • Cheng J
        • Li T
        • et al.
        Efficacy and Toxicity for Cd22/Cd19 Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory Aggressive B-Cell Lymphoma Involving the Gastrointestinal Tract.
        Cytotherapy. 2020; 22: 166-171
        • Neelapu SS
        • Tummala S
        • Kebriaei P
        • et al.
        Chimeric Antigen Receptor T-Cell Therapy—Assessment and Management of Toxicities.
        Nat Rev Clin Oncol. 2018; 15: 47-62
        • Lou Y
        • Chen C
        • Long X
        • et al.
        Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital Pcr Versus Real-Time Pcr.
        J Mol Diagn. 2020; 22: 699-707
        • Ban-Hoefen M
        • Vanderplas A
        • Crosby-Thompson AL
        • et al.
        Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the Nccn Outcomes Database.
        Br J Haematol. 2013; 163: 487-495
        • Doocey RT
        • Toze CL
        • Connors JM
        • et al.
        Allogeneic Haematopoietic Stem-Cell Transplantation for Relapsed and Refractory Aggressive Histology Non-Hodgkin Lymphoma.
        Br J Haematol. 2005; 131: 223-230
        • Reddy N
        • Greer JP
        • Goodman S
        • et al.
        Long-Term Outcome after Autologous or Allogeneic Stem Cell Transplantation in Patients with Recurrent Follicular Lymphoma.
        Bone Marrow Transplant. 2012; 47: 1318-1320
        • Neelapu SS
        • Locke FL
        • Bartlett NL
        • et al.
        Axicabtagene Ciloleucel Car T-Cell Therapy in Refractory Large B-Cell Lymphoma.
        N Engl J Med. 2017; 377: 2531-2544
        • Locke FL
        • Ghobadi A
        • Jacobson CA
        • et al.
        Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (Zuma-1): A Single-Arm, Multicentre, Phase 1-2 Trial.
        Lancet Oncol. 2019; 20: 31-42
        • Nastoupil LJ
        • Jain MD
        • Feng L
        • et al.
        Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results from the Us Lymphoma Car T Consortium.
        J Clin Oncol. 2020; 38: 3119-3128
        • Muranski P
        • Boni A
        • Wrzesinski C
        • et al.
        Increased Intensity Lymphodepletion and Adoptive Immunotherapy—How Far Can We Go?.
        Nat Clin Pract Oncol. 2006; 3: 668-681
        • Ninomiya S
        • Narala N
        • Huye L
        • et al.
        Tumor Indoleamine 2,3-Dioxygenase (Ido) Inhibits Cd19-Car T Cells and Is Downregulated by Lymphodepleting Drugs.
        Blood. 2015; 125: 3905-3916
        • Wrzesinski C
        • Paulos CM
        • Gattinoni L
        • et al.
        Hematopoietic Stem Cells Promote the Expansion and Function of Adoptively Transferred Antitumor Cd8 T Cells.
        J Clin Invest. 2007; 117: 492-501
        • Sim AJ
        • Jain MD
        • Figura NB
        • et al.
        Radiation Therapy as a Bridging Strategy for Car T Cell Therapy with Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
        Int J Radiat Oncol Biol Phys. 2019; 105: 1012-1021
        • Wright CM
        • LaRiviere MJ
        • Baron JA
        • et al.
        Bridging Radiation Therapy before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.
        Int J Radiat Oncol Biol Phys. 2020; 108: 178-188
        • Qu Changju
        • Ping Nana
        • Kang Liqing
        • et al.
        Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma with High Tumor Burden.
        Immunotherapy. 2020; 43: 32-37
        • Yang X
        • Yu Q
        • Xu H
        • Zhou J
        Upregulation of Cd22 by Chidamide Promotes Car T Cells Functionality.
        Sci Rep. 2021; 11: 20637
        • Fraietta JA
        • Beckwith KA
        • Patel PR
        • et al.
        Ibrutinib Enhances Chimeric Antigen Receptor T-Cell Engraftment and Efficacy in Leukemia.
        Blood. 2016; 127: 1117-1127
        • Weber EW
        • Lynn RC
        • Sotillo E
        • Lattin J
        • Xu P
        • Mackall CL
        Pharmacologic Control of Car-T Cell Function Using Dasatinib.
        Blood Adv. 2019; 3: 711-717